📊 LMAT Key Takeaways
Is LMAT a Good Investment? Thesis Analysis
LeMaitre Vascular demonstrates exceptional financial health with fortress-like balance sheet (zero debt, 12.89x current ratio) and outstanding profitability (71.5% gross margin, 27.2% operating margin). Despite flat revenue, net income surged 31% YoY through operational leverage and strong free cash flow generation of $74.5M (29.8% FCF margin). However, sustained topline growth is critical to validate valuation and operational momentum.
Why Buy LMAT? Key Strengths
- Exceptional gross margin of 71.5% and operating margin of 27.2% demonstrates pricing power and operational excellence
- Zero long-term debt with 12.89x current ratio and 11.94x quick ratio indicates fortress balance sheet and exceptional liquidity cushion
- Strong free cash flow generation of $74.5M with 29.8% FCF margin demonstrates capital-efficient business model requiring minimal reinvestment
LMAT Investment Risks to Consider
- Revenue growth completely flat at +0.0% YoY; topline stagnation concerning for medical device sector and unsustainable net income growth trajectory
- Net income growth of 31% is driven by operational leverage on flat revenues, indicating one-time efficiencies or cost-cutting rather than organic growth
- Surgical instruments sector faces intense competitive and pricing pressures that could compress margins without differentiation and innovation pipeline visibility
Key Metrics to Watch
- Revenue growth acceleration - must return to positive topline growth to sustain valuations
- Gross margin stability - monitor for competitive pricing pressures in medical device market
- Free cash flow sustainability and capital allocation decisions - key indicator of management capital discipline
LMAT Financial Metrics
💡 AI Analyst Insight
The 29.8% free cash flow margin provides substantial flexibility for dividends, buybacks, and strategic investments. Strong liquidity with a 12.89x current ratio provides a solid financial cushion.
LMAT Profitability Ratios
LMAT vs Healthcare Sector
How LEMAITRE VASCULAR INC compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is LMAT Overvalued or Undervalued?
Based on fundamental analysis, LEMAITRE VASCULAR INC appears fundamentally strong relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
LMAT Balance Sheet & Liquidity
LMAT 5-Year Financial Trend & Growth Analysis
5-Year Trend Summary: LEMAITRE VASCULAR INC's revenue has grown significantly by 62% over the 5-year period, indicating strong business expansion. The most recent EPS of $1.34 reflects profitable operations.
LMAT Growth Metrics (YoY)
LMAT Quarterly Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q3 2024 | $47.4M | $6.0M | $0.33 |
| Q2 2024 | $50.1M | $6.0M | $0.36 |
| Q1 2024 | $47.1M | $6.0M | $0.27 |
| Q3 2023 | $39.0M | $3.5M | $0.25 |
| Q2 2023 | $42.1M | $3.5M | $0.16 |
| Q1 2023 | $39.6M | $6.0M | $0.27 |
| Q3 2022 | $38.4M | $3.5M | $0.25 |
| Q2 2022 | $40.7M | $3.5M | $0.16 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
LMAT Capital Allocation
LMAT SEC 10-K & 10-Q Filing Analysis
Access official SEC EDGAR filings for LEMAITRE VASCULAR INC (CIK: 0001158895)
📋 Recent SEC Filings
❓ Frequently Asked Questions about LMAT
What is the AI rating for LMAT?
LEMAITRE VASCULAR INC (LMAT) has an AI rating of BUY with 78% confidence, based on fundamental analysis of SEC EDGAR filings.
What are LMAT's key strengths?
Claude: Exceptional gross margin of 71.5% and operating margin of 27.2% demonstrates pricing power and operational excellence. Zero long-term debt with 12.89x current ratio and 11.94x quick ratio indicates fortress balance sheet and exceptional liquidity cushion.
What are the risks of investing in LMAT?
Claude: Revenue growth completely flat at +0.0% YoY; topline stagnation concerning for medical device sector and unsustainable net income growth trajectory. Net income growth of 31% is driven by operational leverage on flat revenues, indicating one-time efficiencies or cost-cutting rather than organic growth.
What is LMAT's revenue and growth?
LEMAITRE VASCULAR INC reported revenue of $249.6M.
Does LMAT pay dividends?
LEMAITRE VASCULAR INC pays dividends, with $18.1M distributed to shareholders in the trailing twelve months.
Where can I find LMAT SEC filings?
Official SEC filings for LEMAITRE VASCULAR INC (CIK: 0001158895) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is LMAT's EPS?
LEMAITRE VASCULAR INC has a diluted EPS of $2.52.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is LMAT a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, LEMAITRE VASCULAR INC has a BUY rating with 78% confidence. The AI analysis suggests favorable fundamentals based on SEC filings. This is not investment advice.
Is LMAT stock overvalued or undervalued?
Valuation metrics for LMAT: ROE of 14.7% (sector avg: 15%), net margin of 23.1% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy LMAT stock in 2026?
Our dual AI analysis gives LEMAITRE VASCULAR INC a combined BUY rating for 2026. Revenue is data pending, with profitability above sector average. Always conduct your own research.
What is LMAT's free cash flow?
LEMAITRE VASCULAR INC's operating cash flow is $81.3M, with capital expenditures of $6.8M. FCF margin is 29.8%.
How does LMAT compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin 23.1% (avg: 12%), ROE 14.7% (avg: 15%), current ratio 12.89 (avg: 2).